ArticleFrontiers in medicine2026
Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis with stage 3-5 chronic kidney disease: a retrospective real-world study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To evaluate dupilumab efficacy and safety in stage 3-5 chronic kidney disease (CKD) patients with moderate-to-severe atopic dermatitis (AD). Methods: This retrospective study included 29 such patients receiving dupilumab who completed 12 and 24 weeks of follow-up. Assessments included Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale ( Results: At week 12, mean EASI score decreased from 34.94 ± 7.96 at baseline to 19.31 ± 6.09 (44.7% reduction), with 76.0% of patients achieving EASI-50. Pruritus NRS decreased from 7.72 ± 1.75 to 3.72 ± 1.75 (51.8% reduction), and 88.0% achieved a ≥ 4-point improvement. DLQI improved by 52.1%, and 100% of patients achieved a ≥ 4-point improvement. CFS score decreased by 17.5%. Eosinophil counts decreased by 25.0%, while IL-10 and Treg proportions increased by 49.9% and 50.8%, respectively. At week 24, EASI-50, EASI-75, and EASI-90 response rates were 100%, 76.9%, and 7.7%, respectively; 100% of patients achieved ≥4-point improvements in both pruritus NRS and DLQI. IL-10 and Treg continued to rise, and CFS score was significantly reduced from baseline ( Conclusion: Dupilumab effectively improves skin lesions, pruritus, sleep, quality of life, and frailty, while showing changes consistent with regulatory immune modulation in patients with stage 3-5 CKD and moderate-to-severe AD, with a favorable safety profile. Renal impairment alone should not be considered an absolute contraindication, although patients with advanced CKD require careful monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.